Top

International Journal of Colorectal Disease

Published in:

01-03-2009 | Original Article

Gene expression profile in colon cancer cells with respect to XIAP expression status

Authors: Liang Qiao, Gloria H. Y. Li, Yun Dai, Jide Wang, Zesong Li, Bing Zou, Qing Gu, Juan Ma, R. Pang, Hui Y. Lan, Benjamin C. Y. Wong

Published in: International Journal of Colorectal Disease | Issue 3/2009

Abstract

Background and aims

We observed a marked synergism between peroxisome proliferator-activated receptor gamma (PPARγ) ligands and X-linked inhibitor of apoptosis (XIAP) down-regulation in colon cancer. In the current study, we detected the gene expression profile in HCT116 cells treated with or without PPARγ ligand troglitazone.

Materials and methods

HCT116-XIAP^+/+ and HCT116-XIAP^−/− cells were treated with or without 50 μM troglitazone for 48 h. Gene expressions were detected by microarray, and selected genes were validated by reverse-transcriptase polymerase chain reaction (PCR), real-time PCR, and Western blot.

Results

Relative to HCT116-XIAP^+/+ cells, 58 genes were up-regulated and 33 genes down-regulated in HCT116-XIAP^−/− cells, all by ≥4-fold. These genes could be classified into a wide variety of functional classes, but we focused on those related to angiogenesis, apoptosis, and proliferation. Thus, two pro-apoptotic genes and one pro-proliferation gene were up-regulated in HCT116-XIAP^−/− cells. Two pro-proliferation genes, one pro-angiogenesis gene, one anti-angiogenesis gene, and one anti-apoptosis gene were down-regulated in HCT116-XIAP^−/− cells. Relative to HCT116-XIAP^+/+ cells treated with troglitazone, 137 genes were up-regulated, and 31 genes were down-regulated in troglitazone-treated HCT116-XIAP^−/− cells, all by ≥4-fold. Among the up-regulated genes were two anti-angiogenesis genes, seven pro-apoptosis genes, and six anti-proliferation genes. Among the down-regulated genes were one anti-angiogenesis gene, one pro-angiogenesis gene, one anti-apoptosis gene, one anti-proliferation gene, and two pro-proliferation genes.

Conclusion

Down-regulation of XIAP in HCT116 cells with or without troglitazone treatment was associated with changes of gene expression that favor increased tendency of apoptosis, decreased cell proliferation, and angiogenesis potential.

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMed

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRef

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRef

Inoue H, Shiraki K, Murata K, Sugimoto K, Kawakita T, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Yamanaka Y, Nakano T (2004) Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 14:271–275PubMed

Marienfeld C, Yamagiwa Y, Ueno Y, Chiasson V, Brooks L, Meng F, Patel T (2004) Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. Gastroenterology 127:1787–1797PubMedCrossRef

Holcik M, Gibson H, Korneluk RG (2001) XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6:253–261PubMedCrossRef

Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, Lu GC (2005) Down-regulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 12:509–514PubMed

Brockman JA, Gupta RA, Dubois RN (1998) Activation of PPARg leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115:1049–1055PubMedCrossRef

Dai Y, Qiao L, Chan KW, Zou B, Ma J, Lan HY, Gu Q, Li Z, Wang Y, Wong BL, Wong BC (2008) Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int J Cancer 122:2858–2863PubMedCrossRef

10.

Qiao L, Dai Y, Chan KW, Chan MaJ, Lin MCM, Lan HY, Gu Q, Zou B, Wong BCY (2008) XIAP deficiency sensitizes PPARγ ligand-induced killing of colon cancer cells. Mol Cancer Ther 7:2203–2211PubMedCrossRef

11.

Qiao L, Dai Y, Gu Q, Chan KW, Ma J, Lan HY, Zou B, Rocken C, Ebert MP, Wong BC (2008) Loss of XIAP sensitizes colon cancer cells to PPARγ independent anti-cancer effects of Troglitazone and 15-PGJ2. Cancer Lett 268:260–271

12.

Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F (2004) X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 64:3006–3008PubMedCrossRef

13.

Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, Siani-Rose MA (2003) NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res 31:82–86PubMedCrossRef

14.

Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA (2003) SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 31:219–223PubMedCrossRef

15.

Maglott D, Ostell J, Pruitt KD, Tatusova T (2005) Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 33:D54–D58PubMedCrossRef

16.

Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A (2003) ExPASy The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 31:3784–3788PubMedCrossRef

17.

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25–29PubMedCrossRef

18.

Shih W, Chetty R, Tsao MS (2005) Expression profiling by microarrays in colorectal cancer (Review). Oncol Rep 13:517–524PubMed

19.

Butt AJ, Firth SM, King MA, Baxter RC (2000) Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275:39174–39181PubMedCrossRef

20.

Hong J, Zhang G, Dong F, Rechler MM (2002) Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277:10489–10497PubMedCrossRef

21.

Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA (2007) IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 28:2154–2159PubMedCrossRef

22.

Shahjee H, Bhattacharyya N, Zappala G, Wiench M, Prakash S, Rechler MM (2007) An N-terminal fragment of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Horm IGF Res 18(3):188–197PubMedCrossRef

23.

Kirman I, Poltoratskaia N, Sylla P, Whelan RL (2004) Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery 136:205–209PubMedCrossRef

24.

Jenkins PJ, Khalaf S, Ogunkolade W, McCarthy K, David T, Hands RE, Davies D, Bustin SA (2005) Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis. Endocr Relat Cancer 12:891–901PubMedCrossRef

25.

H-Zadeh AM, Collard TJ, Malik K, Hicks DJ, Paraskeva C, Williams AC (2006) Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. Int J Oncol 29:1279–1286PubMed

26.

Williams AC, Smartt H, H-Zadeh AM, Macfarlane M, Paraskeva C, Collard TJ (2007) Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-κB. Cell Death Differ 14:137–145PubMedCrossRef

27.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA (2007) Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1a, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72:395–406PubMedCrossRef

28.

Allegrini G, Goulette FA, Darnowski JW, Calabresi P (2004) Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 53:261–266PubMedCrossRef

29.

Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153PubMed

30.

Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC (2005) Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204:36–44PubMedCrossRef

31.

Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, Kanda N, Sekikawa A, Fukui H, Yanagita M, Yoshibayashi H, Satoh S, Sakai Y, Nakano T, Chiba T (2007) Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog 46:155–164PubMedCrossRef

32.

Katoh M, Katoh M (2006) Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. Int J Mol Med 17:681–685PubMed

33.

Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969–8982PubMedCrossRef

34.

Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M (2006) Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB J 20:1009–1011PubMedCrossRef

35.

Siekmann AF, Lawson ND (2007) Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 445:781–784PubMedCrossRef

36.

Robert-Moreno A, Espinosa L, Sanchez MJ, de la Pompa JL, Bigas A (2007) The notch pathway positively regulates programmed cell death during erythroid differentiation. Leukemia 21:1496–1503PubMedCrossRef

37.

Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24:8813–8822PubMedCrossRef

38.

Dickson BC, Mulligan AM, Zhang H, Lockwood G, O’Malley FP, Egan SE, Reedijk M (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20:685–693PubMedCrossRef

39.

Fransson A, Ruusala A, Aspenström P (2003) Atypical Rho GTPases have roles in mitochondrial homeostasis and apoptosis. J Biol Chem 278:6495–6502PubMedCrossRef

40.

41.

Modur V, Nagarajan R, Evers BM, Milbrandt J (2002) FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277:47928–47937PubMedCrossRef

42.

Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13:181–189PubMed

43.

Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89:1161–1167PubMedCrossRef

44.

Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16:742–744PubMed

45.

Okazawa H, Rich T, Chang A, Lin X, Waragai M, Kajikawa M, Enokido Y, Komuro A, Kato S, Shibata M, Hatanaka H, Mouradian MM, Sudol M, Kanazawa I (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34:701–713PubMedCrossRef

46.

Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66:1354–1362PubMedCrossRef

47.

Sivarajasingham NS, Baker R, Tilsed JV, Greenman J, Monson JR, Cawkwell L (2003) Identifying a region of interest in site- and stage-specific colon cancer on chromosome 13. Ann Surg Oncol 10:1095–1099PubMedCrossRef

48.

Olver IN, Hercus T, Lopez A, Vadas M, Somogyi AA, Doyle I, Foster DJ, Keefe D, Taylor A, Brown M, To LB, Cole J, Rawling T, Cambareri B, Myers M, Olszewski N, Bastiras S, Senn C, Hey A, Verma M, Wigley P (2002) A phase I study of the GM-CSF antagonist E21R. Cancer Chemother Pharmacol 50:171–178PubMedCrossRef

49.

Wing LY, Chen HM, Chuang PC, Wu MH, Tsai SJ (2005) The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J Biol Chem 280:19937–19947PubMedCrossRef

50.

Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A (2002) PPARg ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923–932PubMed

Title: Gene expression profile in colon cancer cells with respect to XIAP expression status
Authors: Liang Qiao
Gloria H. Y. Li
Yun Dai
Jide Wang
Zesong Li
Bing Zou
Qing Gu
Juan Ma
R. Pang
Hui Y. Lan
Benjamin C. Y. Wong
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 3/2009
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-008-0566-1

At a glance: The STEP trials

Springer Medicine

Gene expression profile in colon cancer cells with respect to XIAP expression status

Abstract

Background and aims

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background and aims

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2009

Multiple primary cancers in extracolonic sites with colorectal cancer

Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results

Reconstruction of the pelvic floor with a biological mesh after abdominoperineal excision for rectal cancer

Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer

Perioperative and adjuvant chemotherapy in colon cancer: results of SAKK trial 40/93

Acellular porcine cross-linked dermal collagen may be a valuable graft for pelvic floor reconstruction after extended resection